Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis
- 1 April 2011
- journal article
- research article
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 252 (2) , 165-175
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Tyrosine kinases as targets for the treatment of rheumatoid arthritisNature Reviews Rheumatology, 2009
- Regression of fibrosis in paediatric autoimmune hepatitis: morphometric assessment of fibrosis versus semiquantiatative methodsFibrogenesis & Tissue Repair, 2009
- Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemiaClinical Therapeutics, 2008
- Mechanisms of Hepatic FibrogenesisGastroenterology, 2008
- Novel redox-dependent regulation of NOX5 by the tyrosine kinase c-AblFree Radical Biology and Medicine, 2008
- Effects of the Protein Kinase Inhibitor, Imatinib Mesylate, on Epithelial/Mesenchymal Phenotypes: Implications for Treatment of Fibrotic DiseasesThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Imatinib Mesylate (Gleevec) HepatotoxicityDigestive Diseases and Sciences, 2007
- Hepatotoxicity and Mechanism of Action of Haloalkanes: Carbon Tetrachloride as a Toxicological ModelCritical Reviews in Toxicology, 2003
- Improved method for quantification of tissue PMN accumulation measured by myeloperoxidase activityJournal of Pharmacological Methods, 1990
- Estimation of collagen content of liver specimens. Variation among animals and among hepatic lobes in cirrhotic rats.Journal of Histochemistry & Cytochemistry, 1989